Clinical Trial Update: Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer [NA]

View source ↗

Summary

A clinical trial is evaluating neoadjuvant therapy with oral paclitaxel plus subcutaneous pertuzumab and trastuzumab for HER2-positive breast cancer. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)
• paclitaxel (oral formulation) (paclitaxel)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Breast Cancers | NA | Status: RECRUITING